Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study

Canadian Journal of Veterinary Research

Volumn 77, Issue 2, 2013, Pages 142-149

  Kim, Jong Hyuk ^a,c   Chon, Seung Ki ^b   Im, Keum Soon ^a   Kim, Na Hyun ^a   Sur, Jung Hyang ^a  

^a Konkuk University   (South Korea)

^b Hyu Animal Clinic   (South Korea)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD79 ANTIGEN; CYTOKERATIN 14; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN P63;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CELL STRUCTURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOG; FEMALE; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, ANIMAL; PHENOTYPE;

EID: 84875703249     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
2. O'Sullivan C, Lewis CE. Tumour-associated leucocytes: Friends or foes in breast carcinoma. J Pathol 1994;172:229-235.
3. Ben-Baruch A. Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: Reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003;5:31-36.
4. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007;9:212.
5. Moss RB, Moll T, El-Kalay M, et al. Th1/Th2 cells in inflammatory disease states: Therapeutic implications. Expert Opin Biol Ther 2004;4:1887-1896.
6. Munk ME, Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J Suppl 1995;20:668s-675s.
7. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007;19:209-216.
8. Johansson M, Tan T, de Visser KE, Coussens LM. Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem 2007;101:918-926.
9. Rutten VP, Misdorp W, Gauthier A, et al. Immunological aspects of mammary tumors in dogs and cats: A survey including own studies and pertinent literature. Vet Immunol Immunopathol 1990;26:211-225.
10. Rivera P, von Euler H. Molecular biological aspects on canine and human mammary tumors. Vet Pathol 2011;48:132-146. Epub 2010 Dec 7.
11. Queiroga FL, Raposo T, Carvalho MI, Prada J, Pires I. Canine mammary tumours as a model to study human breast cancer: Most recent findings. In Vivo 2011;25:455-465.
12. Estrela-Lima A, Araujo MS, Costa-Neto JM, et al. Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 2010;10:256.
13. Carvalho MI, Pires I, Prada J, Queiroga FL. T-lymphocytic infiltrate in canine mammary tumours: Clinic and prognostic implications. In Vivo 2011;25:963-969.
14. Saeki K, Endo Y, Uchida K, Nishimura R, Sasaki N, Nakagawa T. Significance of tumor-infiltrating immune cells in spontaneous canine mammary gland tumor: 140 cases. J Vet Med Sci 2012;74:227-230. Epub 2011 Sep 22.
15. Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: Application of the human classification. Virchows Arch 2008;453:123-132.
16. Sassi F, Benazzi C, Castellani G, Sarli G. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res 2010;6:5.
17. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: Three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447:688-694. Epub 2005 Oct 19.
18. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 2006;37:1217-1226.
19. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:0869-10874.
20. Alexe G, Dalgin GS, Scanfeld D, et al. High expression of lymphocyte-associated genes in node-negative HER21 breast cancers correlates with lower recurrence rates. Cancer Res 2007; 67:10669-10676.
21. Baxevanis CN, Sotiriadou NN, Gritzapis AD, et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 2006;55:85-95.
22. Milano F, Guarriera M, Rygiel AM, Krishnadath KK. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One 2010;5:e12424.
23. Misdorp W, Else RW, Hellmen E, Lipscomb TP. Histological classification of mammary tumors of the dog and the cat. In: International Histological Classification of Tumors of Domestic Animals. Washington DC: Armed Forces Institute of Pathology, 1999:18-25.
24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 2002;41:154-161.
25. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: Application of a human grading method. J Comp Pathol 2005;133:246-252.
26. Kim JH, Im KS, Kim NH, Yhee JY, Nho WG, Sur JH. Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: Histopathological and immunohistochemical study. Vet J 2011;189:318-322.
27. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209:445-453.
28. Kim JH, Yu CH, Yhee JY, Im KS, Kim NH, Sur JH. Canine classical seminoma: A specific malignant type with human classifications is highly correlated with tumor angiogenesis. BMC Cancer 2010;10:243.
29. Misdorp W. Tumors of the mammary gland. In: Meuten DJ, ed. Tumors in Domestic Animals. 4th ed. Ames, Iowa: Iowa State University Press, 2002:575-606.
30. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003; 52:715-738.
31. Wong PY, Staren ED, Tereshkova N, Braun DP. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. J Surg Res 1998;76:95-103.
32. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 1992;12:1463-1466.
33. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.